In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by Joint Accreditation for Interprofessional Continuing Education policies and accreditation requirements including the Standards for Integrity and Independence in Accredited Continuing Education, AAAP is expected to present learners with unbiased, independent, and objective information in all our activities. Therefore, members, authors, reviewers, and all others involved in the planning or content development of this activity must disclose all financial and professional relationships within the past 24 months. These disclosures have been reviewed and all relevant relationships have been mitigated. All others involved in the planning and presentation of this activity have no relevant relationships to disclose.

The following planner has relevant relationships to disclose:

Ellen Edens, MD  Aspire 365  Advisory Board

The following faculty have relevant relationships to disclose:

Smita Das, MD  Lyra Health  Stock/Equity
Jeffrey DeVido, MD  Altria/Philip Morris  Stock/Equity
Merck  Stock/Equity
Greenwich Sciences  Consultant
Kevin Hill, MD  Hazelden  Stipend
Frances Levin, MD  Alkermes  Material Support
Indivior Pharmaceuticals  US World Meds
Alain Litwin, MD  Gilead Sciences  Advisory Board; Principal Investigator
Merck  Advisory Board
Edward Nunes, MD  Alkermes  In-kind support (medication donated)
Indivior  In-kind support (medication donated)
Pear Therapeutics  In-kind (digital therapeutic donated)
Stephen Ross, MD  Reset Pharmaceuticals Research Grant  Principal Investigator
Research Grant  Principal Investigator
USona Institute Research Grant  Consultant
Sandra Springer, MD  Alkermes Inc  Honoraria
Alkermes Inc  Material Support
Indivior Pharmaceutical Company
Timothy Wilens, MD  3D Therapeutics  Consultant
Bay Cove Human Services  Consultant
Ironshore  Consultant
Arthur Robin Williams, MD  Ophelia Health Inc  Material Support

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All
scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis.